Tumors of low malignant potential a single institution experience.
Borderline
Ovaries
Surgery
Treatment
Journal
International journal of surgery case reports
ISSN: 2210-2612
Titre abrégé: Int J Surg Case Rep
Pays: Netherlands
ID NLM: 101529872
Informations de publication
Date de publication:
2019
2019
Historique:
received:
19
06
2018
revised:
19
12
2018
accepted:
14
01
2019
pubmed:
27
1
2019
medline:
27
1
2019
entrez:
27
1
2019
Statut:
ppublish
Résumé
The tumors of low malignant potential are an independent group of the ovarian epithelial tumors. They represents 10-20% of all ovarian epithelial tumors. Our aim through this study to determine how to treat this disease in the most suitable way. A retrospective study involving 73 patients diagnosed with TLMP and treated at our Institute between September 1975 and June 2010. The median age was 49 years. In 33% of the cases, the patients were younger than 40 years. Our study included 38 mucinous tumors, 30 serous and 5 mixed. The tumors were stage I in 69% of the cases, stage II in 11% and stage III in 20%. All patients had surgery as a primary treatment. The surgery was radical in 77% of the cases. Five patients had an adjuvant chemotherapy. After a mean follow up of 10 years, we reported 7 cases of local relapses. The prognostic factors for a disease free survival were: the stage of the tumor and the presence of invasive implants. The overall survival at 5 and 10 years was respectively of 96.9% and 92.8%. The prognostic factors for overall survival were: the age, the stage, the existence of a residual tumor, the presence of pseudomyxoma or peritoneal implants. After having a conservative surgery two patients achieved full term pregnancies. Randomized studies are required to back-up our findings and give a higher grade of recommendation to the actual standard of care.
Sections du résumé
BACKGROUND
BACKGROUND
The tumors of low malignant potential are an independent group of the ovarian epithelial tumors. They represents 10-20% of all ovarian epithelial tumors. Our aim through this study to determine how to treat this disease in the most suitable way.
METHODS
METHODS
A retrospective study involving 73 patients diagnosed with TLMP and treated at our Institute between September 1975 and June 2010.
RESULTS
RESULTS
The median age was 49 years. In 33% of the cases, the patients were younger than 40 years. Our study included 38 mucinous tumors, 30 serous and 5 mixed. The tumors were stage I in 69% of the cases, stage II in 11% and stage III in 20%. All patients had surgery as a primary treatment. The surgery was radical in 77% of the cases. Five patients had an adjuvant chemotherapy. After a mean follow up of 10 years, we reported 7 cases of local relapses. The prognostic factors for a disease free survival were: the stage of the tumor and the presence of invasive implants. The overall survival at 5 and 10 years was respectively of 96.9% and 92.8%. The prognostic factors for overall survival were: the age, the stage, the existence of a residual tumor, the presence of pseudomyxoma or peritoneal implants. After having a conservative surgery two patients achieved full term pregnancies.
CONCLUSION
CONCLUSIONS
Randomized studies are required to back-up our findings and give a higher grade of recommendation to the actual standard of care.
Identifiants
pubmed: 30684818
pii: S2210-2612(19)30012-4
doi: 10.1016/j.ijscr.2019.01.001
pmc: PMC6351433
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
41-46Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
Eur J Cancer. 2015 Mar;51(5):620-31
pubmed: 25661104
Cancer. 1998 Mar 15;82(6):1096-103
pubmed: 9506355
Lancet Oncol. 2012 Mar;13(3):e103-15
pubmed: 22381933
J Am Coll Surg. 2002 Sep;195(3):332-8
pubmed: 12229940
Ann Surg Oncol. 2006 Apr;13(4):565-71
pubmed: 16491337
Rev Prat. 2004 Oct 31;54(16):1770-6
pubmed: 15630881
Best Pract Res Clin Obstet Gynaecol. 2012 Jun;26(3):325-36
pubmed: 22321906
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S5-8
pubmed: 25341581
Eur J Cancer. 2013 May;49(8):1905-14
pubmed: 23490647
Am J Surg Pathol. 2000 Nov;24(11):1465-79
pubmed: 11075848
Int J Surg. 2016 Dec;36(Pt A):319-323
pubmed: 27770639
Yale J Biol Med. 1989 Jul-Aug;62(4):351-65
pubmed: 2556863
Gynecol Obstet Fertil. 2006 Jun;34(6):470-8
pubmed: 16677839
Oncologist. 2012;17(12):1515-33
pubmed: 23024155
Am J Obstet Gynecol. 2011 May;204(5):438.e1-7
pubmed: 21349494
Gynecol Oncol. 2014 Jan;132(1):23-7
pubmed: 24219980
Am J Surg Pathol. 2010 Jan;34(1):1-9
pubmed: 19898226
Hum Reprod Update. 2003 Mar-Apr;9(2):185-92
pubmed: 12751780
Gynecol Obstet Fertil. 2008 Apr;36(4):422-9
pubmed: 18356093
Hum Pathol. 2000 May;31(5):539-57
pubmed: 10836293